Last reviewed · How we verify
ELACESTRANT HYDROCHLORIDE
ELACESTRANT HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 2023).
Elacestrant Hydrochloride is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the potential for increased competition as the patent expiration approaches.
At a glance
| Generic name | ELACESTRANT HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2023 |
Approved indications
Common side effects
Key clinical trials
- Ph 2 Elacestrant in ER Positive Uterine Sarcomas (PHASE2)
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ELACESTRANT HYDROCHLORIDE CI brief — competitive landscape report
- ELACESTRANT HYDROCHLORIDE updates RSS · CI watch RSS
Frequently asked questions about ELACESTRANT HYDROCHLORIDE
What is ELACESTRANT HYDROCHLORIDE?
When was ELACESTRANT HYDROCHLORIDE approved?
What development phase is ELACESTRANT HYDROCHLORIDE in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing